We have combined our expertise with that of several collaborators at UCLA, Charles Perkins Centre and the Baker Institute to establish a state-of-the-art discovery platform. This platform has the power to associate quantitative readouts from liver proteomic and lipidomic analyses, with phenotypes of cardiometabolic disease in >100 strains of genetically diverse, inbred mouse lines. To our knowledge this is the largest discovery platform of its kind in the world, maximising our opportunity to identify potentially significant molecular targets. Our group aims to use these datasets to identify novel links between mitochondrial function, lipid metabolism and cardiometabolic disease.
